LLY Dec 2025 650.000 call
| Previous close | 177.57 |
| Open | 177.57 |
| Bid | 239.00 |
| Ask | 248.00 |
| Strike | 650.00 |
| Expiry date | 2025-12-19 |
| Day's range | 177.57 - 177.57 |
| Contract range | N/A |
| Volume | |
| Open interest | 61 |
Investor's Business DailyDow Jones Futures: Apple AI Push, Tesla, Fed Loom For Stock Market
The stock market is at highs with Apple's AI push, the Fed rate "dot-plot" and the Tesla shareholder meeting headlining key events and news.
PR NewswireLilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks
Eli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate the investigational use of tirzepatide in adults with biopsy-proven metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis. The efficacy estimandi showed 51.8%, 62.8% and 73.3% of participants taking 5 mg, 10 mg and 15 mg, respectively, achieved an absence of MASH with no worsening of fibrosis on liver histology
Investor's Business DailyEli Lilly Is Trading At A Record High Ahead Of A Key FDA Meeting — Is It A Buy?
Eli Lilly stock is climbing higher ahead of an FDA meeting to discuss its Alzheimer's treatment. Is LLY stock a buy right now?
